Histology
Carcinoma of Unknown Primary
CI-CAN-00002109Explore in graph →
4,156 active trials54 approved drugs532 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00002109Explore in graph →
Clinical trials
14,232 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,893)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06558227 | Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 90 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06725121 | Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant(MacroTrans) | recruiting | Phase 1 / Phase 2 | 48 | University Health Network, TorontoOTHER | 1 | Dec 16, 2024 |
| clinicaltrials |
| NCT06736054 | A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer | recruiting | Phase 1 | 8 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06636981 | All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial | recruiting | Phase 2 | 129 | Fudan UniversityOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT05668962 | Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC | recruiting | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06496048 | Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC | recruiting | Phase 3 | 180 | Luye Pharma Group Ltd.INDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06725498 | Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC | recruiting | Phase 2 | 50 | Beijing Tongren HospitalOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT06727162 | The Value of CEUS in Assessing the Response of Cervical Lymph Nodes After NACI for HNSCC | recruiting | — | 100 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT06727370 | Cognitive Screening in Lung Cancer Patients | recruiting | — | 200 | European Institute of OncologyOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT02185443 | Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases | recruiting | Phase 2 | 43 | University of Sao PauloOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT05937295 | FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition(FusionVAC22) | recruiting | Phase 1 | 20 | University Hospital TuebingenOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06722599 | Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients(LRNacHER2) | recruiting | — | 171 | Shu WangOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06722612 | Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer(TaxCbHER2) | recruiting | — | 2,916 | Shu WangOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT05185739 | Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)(PRIMER-1) | recruiting | Phase 2 | 60 | University College, LondonOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT05655260 | PErsonalized TReatment for Endometrial Carcinoma(PETREC) | recruiting | N/A | 300 | University of HelsinkiOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT02572778 | Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer(UCL-Xenog) | recruiting | — | 40 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT05254197 | SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)(SOLOMON) | recruiting | — | 3,000 | Seoul National University HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06278857 | SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)(SATELLITE) | recruiting | Phase 2 | 10 | Queensland Centre for Gynaecological CancerOTHER_GOV | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06603402 | Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC | recruiting | Phase 2 | 41 | Sichuan UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06609850 | The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma | recruiting | N/A | 116 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06609863 | dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma | recruiting | N/A | 27 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06609876 | Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC | recruiting | N/A | 108 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06644430 | Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma | recruiting | — | 470 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06714604 | Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC(ADVANTAGE) | recruiting | Phase 3 | 432 | Sahlgrenska University HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06444009 | A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 90 | Lei LiuOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT06711055 | Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer(TaxHER) | recruiting | — | 285 | Shu WangOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT06711068 | Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy(TaxDHER2) | recruiting | — | 8,077 | Shu WangOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT06711211 | Spanish Registry of Digestive Tumours RETUD(RETUD) | recruiting | — | 20,000 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT05475613 | Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation | recruiting | Phase 2 | 59 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT05484908 | Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC | recruiting | N/A | 60 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT05945745 | Molecular Analysis and Treatment Options of SCLC | recruiting | — | 500 | Shanghai Chest HospitalOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06709417 | A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS) | recruiting | Phase 2 | 52 | Shanghai Chest HospitalOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06709885 | HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer | recruiting | Phase 2 | 100 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06710665 | Tumor Regression Grade As Predictor of Adjuvant Therapy | recruiting | — | 400 | Fujian Medical University Union HospitalOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT05967143 | Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)(SIRtain) | recruiting | — | 845 | Sirtex MedicalINDUSTRY | 3 | Nov 27, 2024 | clinicaltrials |
| NCT06211114 | Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma | recruiting | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06475118 | Comparison of Serum Myokine Dosages and Imaging Methods in the Evaluation of Sarcopenia in Patients With Hepatocellular Carcinoma(Myomachia) | recruiting | N/A | 139 | CHU de ReimsOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06538896 | Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study | recruiting | Phase 2 | 20 | Zhejiang Cancer HospitalOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT05824975 | A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | recruiting | Phase 1 / Phase 2 | 358 | GI Innovation, Inc.INDUSTRY | 2 | Nov 25, 2024 | clinicaltrials |
| NCT06652243 | Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma(SN301A) | recruiting | Early Phase 1 | 12 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06700369 | De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients(NacHER2) | recruiting | — | 519 | Shu WangOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06700382 | Different Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC(NeoTNBCX) | recruiting | — | 1,166 | Shu WangOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT03812874 | A Study of PTX-9908 Injection for Non-resectable HCC with TACE | recruiting | Phase 1 / Phase 2 | 50 | TCM Biotech International Corp.INDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06698965 | Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin | recruiting | Phase 2 | 52 | Shanghai Chest HospitalOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06301399 | Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study | recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06628661 | Ten-Year Outcomes of Operable Solitary Hepatocellular Carcinoma Patients: Impact of Tumor Size Over 6.5 cm and Microvascular Invasion | recruiting | — | 3,000 | Chang Gung Memorial HospitalOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06631443 | Asian Watch-and-Wait Database (AWWD)(AWWD) | recruiting | — | 337 | Tata Memorial CentreOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06692725 | De-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBC(NacTNBC) | recruiting | — | 380 | Peking University People's HospitalOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06693024 | Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer(NeraHER2) | recruiting | — | 2,806 | Shu WangOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06693037 | Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy(nonPHER) | recruiting | — | 2,092 | Shu WangOTHER | 1 | Nov 20, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Dec 16, 2024source: clinicaltrials